Dr. Aamr A. Herekar, M.D.
Neurology (Neurology Physician)
7100 Westwind Dr Ste 300
El Paso, TX 79912
Who else practices at this address →
El Paso County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 612
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TX license Q7055 (first issued 2016; active) · NM license MD2011-0069 -
Internal Medicine Physician
NM license RS20070418 -
Sleep Medicine (Psychiatry & Neurology) Physician
TX license Q7055 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Medical Center Las Cruces, NM
- University Medical Center of El PAso El PAso, TX
- The Hospitals of Providence - Memorial Campus El PAso, TX
- The Hospitals of Providence Transmountain Campus El PAso, TX
Medical groups
- Herekar PLLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 612
- Services billed
- 5,834
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 458 | 218 |
| Established patient office or other outpatient visit, 30-39 minutes | 297 | 191 |
| New patient office or other outpatient visit, 60-74 minutes | 133 | 133 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 133 | 14 |
| Insertion of needle into vein (3 years or older) | 106 | 18 |
| Measurement of brain wave activity (eeg), digital analysis | 105 | 102 |
| Measurement of brain wave activity (eeg), awake and asleep | 94 | 94 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 62 | 12 |
| Established patient office or other outpatient visit, 20-29 minutes | 61 | 15 |
| Sleep study including heart rate, breathing, and sleep time | 58 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Memantine Hcl Other prescribers in El PAso, TX | 369 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in El PAso, TX | 141 |
| Quetiapine Fumarate Other prescribers in El PAso, TX | 122 |
| Nortriptyline Hcl Other prescribers in El PAso, TX | 97 |
| Donepezil Hcl Other prescribers in El PAso, TX | 94 |
| Levetiracetam Other prescribers in El PAso, TX | 92 |
| Gabapentin Other prescribers in El PAso, TX | 80 |
| Propranolol Hcl Other prescribers in El PAso, TX | 77 |
| Topiramate Other prescribers in El PAso, TX | 66 |
| Botox (onabotulinumtoxina) | 60 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 161 payments worth $5,018 in total to this clinician.
| UCB, Inc. | $521 |
|---|---|
| Alexion Pharmaceuticals, Inc. | $345 |
| Lilly USA, LLC | $327 |
| AbbVie Inc. | $318 |
| EMD Serono, Inc. | $296 |
| Novartis Pharmaceuticals Corporation | $282 |
| Pfizer Inc. | $263 |
| Jazz Pharmaceuticals Inc. | $233 |
| Food and Beverage | $4,748 |
|---|---|
| Consulting Fee | $200 |
| Education | $69.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Scientific Affairs, LLC Feb 14, 2025 | Consulting Fee SPRAVATO · Neuroscience | $200 |
| Harmony Biosciences LLC Jun 25, 2025 | Education in-kind | $69.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 17 industry-funded studies in 2025, from 11 companies. The companies reported $343,850 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Genzyme Corporation · Active, not recruiting · NCT06141473 - A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
ModernaTX, Inc. · Recruiting · NCT06735248 - A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06585787 - A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT07011732 - A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
Eli Lilly and Company · Terminated · NCT06220669 - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
E.r. Squibb & Sons, L.l.c. - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
AbbVie Inc. · Completed · NCT05771428 - Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
Eli Lilly and Company · Completed · NCT05412004 - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
Celgene Corporation - Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.